Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PTH1R | Q03431 | 8/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26374211 | 1.00 | RXFP1 (0.48) | RXFP1PTH1RBACE1GRIN2DGRIN3B | |
| SCHEMBL30262011 | 0.84 | TASP1 (0.53) | PTH1RBACE1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL9751911 | 0.83 | BACE1 (0.57) | PTH1RBACE1 | |
| SCHEMBL9751906 | 0.83 | BACE1 (0.57) | PTH1RBACE1 | |
| SCHEMBL31182621 | 0.82 | BACE1 (0.53) | RXFP1PTH1RBACE1 | |
| SCHEMBL9751909 | 0.82 | BACE1 (0.46) | RXFP1PTH1RBACE1GRIN2DGRIN3B | |
| SCHEMBL30703114 | 0.82 | BACE1 (0.47) | PTH1RBACE1ENPEP | |
| SCHEMBL9751907 | 0.82 | BACE1 (0.46) | RXFP1PTH1RBACE1GRIN2DGRIN3B | |
| SCHEMBL30512613 | 0.81 | GRIN2D (0.47) | RXFP1PTH1RBACE1GRIN2DGRIN3B | |
| SCHEMBL30980374 | 0.81 | BACE1 (0.54) | PTH1RBACE1TASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312652-A1 | NOVEL PEPTIDES AND USES THEREOF | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312652-A1 | NOVEL PEPTIDES AND USES THEREOF | VIP, OPRL1, BDNF | RXFP1 62/4885PTH1R 594/4885BACE1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.